This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Tuesday's Health Winners & Losers

Shares of heart-device developer Vasogen (VSGN) jumped after the company announced positive clinical-trial data at a cardiology meeting.

According to data presented at the World Congress of Cardiology meeting in Barcelona, Spain, a trial involving 2,400 patients with chronic heart failure showed that the company's Celacade technology reduced the risk of death and cardiovascular hospitalization by 31%. Shares were up 19.7% to 68 cents.

Applied Biosystems (ABI) was higher after the company reached a settlement with life-sciences company Promega resolving two legal disputes. Terms of the settlement were not disclosed. Shares were up 1.3% to $31.71.

Oscient Pharmaceuticals (OSCI) sank after the company announced an agreement with Auxilium Pharmaceuticals (AUXL) to conclude a marketing partnership for the testosterone gel Testim.

According to the agreement, Oscient and Auxilium will share profits from sales through Aug. 31. Auxilium will pay Oscient $1.8 million in compensation for Oscient's salesforce efforts. Oscient fell 7.5% to $1.11, while Auxilium dipped 0.6% to $8.60.

German drug giant Bayer (BAY) slipped 1.2% to $48.92 after the company announced the expansion of the Shanghai production facilities at its chemicals subsidiary. The facilities will produce polycarbonate and polyurethane.

SkyePharma (SKYE) declined despite an announcement Monday that the extended-release drug Requip delayed symptom recurrence in patients with Parkinson's disease. The extended release version of Requip, a GlaxoSmithKline (GSK) drug, was developed by SkyePharma using its proprietary controlled-release technology. Shares fell 1.7% to $4.70.

Among other stocks on the move were Northfield Laboratories (NFLD), whose shares dipped 1.3% to $10.58, Avalon Pharmaceuticals (AVRX), down 1.4% to $2.82, and Sanofi-Aventis (SNY), off 1.5% to $44.67.

Progenics Pharmaceuticals (PGNX) rose 12.5% to $25.50, Nuvelo (NUVO) was up 1.2% to $20.78, and Accentia Biopharmaceuticals (ABPI) gained 2.6% to $3.09.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ABI $22.98 1.01%
AAPL $128.17 1.40%
FB $80.75 -0.57%
GOOG $573.54 -0.31%
TSLA $196.70 -2.00%


DOW 17,968.49 -167.23 -0.92%
S&P 500 2,089.56 -11.48 -0.55%
NASDAQ 4,971.4740 -11.3350 -0.23%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs